Metformin for the Minimization of Geographic Atrophy Progression in Patients With AMD

Age-Related Macular Degeneration Clinical Trial

— METforMIN  

Official title:

METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular Degeneration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02684578
• Other study ID #: 15-18258
• Status: Completed
• Phase: Phase 2
• Start date: April 2016
• Est. completion date: October 2022

Study information

• Verified date: May 2023
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether metformin, an FDA-approved drug for the treatment of type II diabetes, is a safe and effective treatment to decrease the progression of geographic atrophy in non-diabetic patients with Age-related Macular Degeneration (AMD).

Description:

This is a phase II, single-blind, randomized, evaluation of the safety and efficacy of metformin use to decrease geographic atrophy (GA) progression in non-diabetic patients with dry Age-related Macular Degeneration (AMD). Approximately 186 study subjects throughout four separate study sites will be randomized in a 1:1 ratio to the treatment group and the observation group. The treatment group will be assigned to the study intervention (oral Metformin) for 18 months while the observation group will receive no intervention for 18 months, instead continuing with standard of care ophthalmic exams and close monitoring of their disease. There will be one additional follow up visit at 24 months. Throughout the 24 month study period, the progression of subjects' GA or drusen growth will be measured via ocular imaging taken at standard of care follow-up examinations, including fundus autofluorescence imaging, optical coherence tomography (OCT), and fundus photography.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 66
• Est. completion date: October 2022
• Est. primary completion date: April 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 55 Years and older

Eligibility

Inclusion Criteria:

• Subject must be >/= 55 years of age

• Subject must have evidence of advanced dry AMD, defined by the characteristic presence of drusen and/or pigmentary changes as well as geographic atrophy

• Subject must have clear ocular media and adequate pupillary dilation

• Subject must be able to swallow capsules

• Study eye must have best corrected visual acuity (BCVA) of 20/20-20/400

• Subject must be willing and able to pay for monthly prescription of Metformin HCl for 18 months in the event that their insurance carrier will not cover the cost of the drug

Exclusion Criteria:

• Subjects with insufficient baseline size of geographic atrophy, less than 1.25 mm2 (0.5 Macular Photocoagulation Study Disc Areas). GA is defined as one or more well-defined and often circular patches of partial or complete depigmentation of the RPE, typically with exposure of underlying choroidal blood vessels. Even if much of the RPE appears to be preserved and large choroidal vessels are not visible, a round patch of RPE partial depigmentation may be classified as early GA. The GA in the study eye must be able to be photographed in its entirety, and it must not be contiguous with any areas of peripapillary atrophy, which can complicate area measurements.

• Subjects who are already taking metformin for another purpose

• Subjects with type 1 or 2 diabetes

• Subjects with compromised kidney function:

• Serum creatinine =1.5 mg/dL for males and =1.4 mg/dL for females

• Subjects with moderate to severe heart failure (Class III or IV, New York Heart Association Functional Classifications)

• Subjects with Child's class C cirrhosis

• Evidence of retinal atrophy due to causes other than atrophic AMD.

• Subjects who have had anti-VEGF injections or active choroidal neovascularization in the study eye during the last 12 months

• Current evidence or history of ocular disorders in the study eye that in the opinion of the investigator confounds study outcome measures, including (but not limited to):

1. Non-proliferative diabetic retinopathy involving 10 or more hemorrhages or microaneurysms, or active proliferative diabetic retinopathy

2. Branch or central retinal vein or artery occlusion

3. Macular hole

4. Pathologic myopia

5. Uveitis

6. Pseudovitelliform maculopathy

7. Intraoperative surgery within the last 90 days prior to study eye enrollment

Related Conditions & MeSH terms

• Age-Related Macular Degeneration
• Atrophy
• Dry Macular Degeneration
• Geographic Atrophy
• Macular Degeneration
• Macular Degeneration, Age-Related

Intervention

Drug:
• Metformin

Locations

Country	Name	City	State
United States	Austin Retina Associates	Austin	Texas
United States	Northwestern University	Chicago	Illinois
United States	University of Illinois at Chicago	Chicago	Illinois
United States	University of California, Davis	Davis	California
United States	Retina Health Center	Fort Myers	Florida
United States	Palo Alto Veteran Affairs Medical Center	Palo Alto	California
United States	Oregon Health and Science University	Portland	Oregon
United States	Retinal Consultants Medical Group	Sacramento	California
United States	San Francisco Veteran Affairs Medical Center	San Francisco	California
United States	University of California San Francisco	San Francisco	California
United States	California Retina Consultants	Santa Maria	California
United States	North Bay Vitreoretinal Consultants	Santa Rosa	California

Sponsors (11)

Lead Sponsor	Collaborator
University of California, San Francisco	California Retina Consultants, Northwestern University, Oregon Health and Science University, Retina Health Center, Retinal Consultants Medical Group, San Francisco Veterans Affairs Medical Center, University of California, Davis, University of California, San Diego, University of Illinois at Chicago, VA Palo Alto Health Care System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fundus Autofluorescence Imaging to Measure the Rate of Change in Area of Geographic Atrophy	The primary efficacy endpoint was the annualized growth rate of the square root of geographic atrophy (GA) area in mm/year in the study eye as imaged by fundus autofluorescence (FAF) imaging. Change = (Month 18 GA Area - Baseline GA Area).	0 months, 18 months
Secondary	Change in Best Corrected Visual Acuity (BCVA)	BCVA is the best possible vision an eye can see with corrective lenses and is measured as then number of letters read on the ETDRS chart. Change = (Month 18 Score - Baseline Score).	0 months, 18 months
Secondary	Change in Low-luminance Visual Acuity (LLVA)	LLVA involves standard BCVA testing in low-light conditions, which is achieved by adding a neutral density filter in front of the eye being tested. LLVA is measured as the number of letters read on the ETDRS chart. This measure has been shown to correlate well with enlargement of GA. Change = (Month 18 Score - Baseline Score).	0 months, 18 months
Secondary	Ocular Safety as Measured by the Presence of Novel Intraocular Inflammation Judged by the Investigator to be Due to the Study Drug Metformin	Subjects assigned to the Metformin study arm will be assessed at each follow-up eye exam to confirm ocular safety of metformin. The Data Safety and Management Board for this study will also assess the safety of metformin at different time points throughout the study. They will formally meet to discuss study subject safety at 25% enrollment and 75% enrollment. The potential for ocular side effects due to metformin is thought to be very low, due to the large number of diabetic patients who take this drug and are followed closely for diabetic retinopathy or other ocular disease.; This outcome measures the number of treatment arm patients who experienced adverse ocular events during 1 or more follow-up visits.	0 months, 6 months, 12 months, 18 months, 24 months
Secondary	Systemic Safety as Measured by Presence of Side Effects Listed on Metformin Drug Label as "Severe"	These include: Infrequent side effects of metformin (severe): Trouble Breathing; Rare side effects of metformin (severe): Increased Blood Acidity due to High Levels of Lactic Acid (Lactic acidosis); Low Blood Sugar; Megaloblastic Anemia; Reaction due to an Allergy; Subjects assigned to the Metformin study arm will be assessed for these side-effects at each follow-up eye exam to confirm ocular safety of metformin. The Data Safety and Management Board for this study will also assess the safety of metformin at different time points throughout the study. They will formally meet to discuss study subject safety at 25% enrollment and 75% enrollment.; This outcome measures the number of treatment arm patients who experienced side effects listed on Metformin drug label as "severe" during 1 or more follow-up visits.	0 months, 6 months, 12 months, 18 months, 24 months